Hepatocellular carcinoma HCC is the sixth most commonly diagnosed cancer worldwide. Sorafenib is an oral multikinase inhibitor used in the palliative treatment of advanced HCC. However, there were no reported cases of complete response CR from two previous large phase clinical trials. Here, we report a case of CR in a patient with advanced HCC with multiple lymph node and bone metastases, treated with sorafenib monotherapy for 8 months. To our knowledge, this is the rst evidence showing CR following sorafenib monotherapy for HCC with bone metastasis.
Introduction
Hepatocellular carcinoma HCC is the sixth most commonly diagnosed cancer and the fourth leading cause of cancer-related mortality 1 . The majority of HCC patients present with advanced and multifocal disease at the time of diagnosis, with a median survival of less than 6 months. Satisfactory outcomes have not been achieved by traditional treatment of advanced HCC using conventional antineoplastic drugs 2 3 . Sorafenib, a multi-target tyrosine kinase inhibitor used in the palliative treatment of advanced HCC, was shown to improve patient survival in two randomized, double-blind, placebo-controlled trials : the Sorafenib HCC Assessment Randomized Protocol SHARP trial and a trial conducted in the Asia-Pacific region 4 5 . However, neither study reported complete response CR to treatment. Here, we present a case of a 67-yearold man with HCC with multiple lymph node and bone metastases who achieved CR following treatment using sorafenib monotherapy for 8 months.
Case report
This report involves a 67-year-old Japanese man with known hypertension and hyperuricemia, who was diagnosed with liver injury and hepatitis C virus infection, which he chose not to treat, during a medical examination in 2006.
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In 2009, he presented with general malaise and sought treatment. Upon examination, computed tomography CT revealed a 37-mm HCC at segment 5 S5 of the liver; hence, he subsequently underwent partial hepatectomy. Histopathological examination revealed moderately differentiated HCC with chronic hepatitis New-Inuyama F3 / A2 . His resection stump was negative. Two years post-partial hepatectomy, he was treated using pegylated interferon IFN -2b and ribavirin therapy for 48 weeks and achieved a sustained virological response. However, in July 2012, CT showed multiple new HCCs four locations : S3 and S5 in both lobes. Recurrence of the S5 HCC was also determined. The S3 and S5 HCCs were treated using enucleation, while the others were treated with radiofrequency ablation.
In March 2013, CT showed multiple lymph node metastases around the liver. Three months later, he also exhibited a 12-mm local recurrence around the S5 operation site along with multiple bone metastases located within the cervical spine C3 , thoracic spine Th4 , and lumbar spine L1, L2, L4, and L5 , identified using magnetic resonance imaging Fig. 1 . The patient, however, was asymptomatic. His Child-Pugh score was A and his Eastern Cooperative Oncology Group performance status was 0. His -fetoprotein AFP levels were 57 ng/ml and his protein induced by vitamin K absence or antagonist PIVKA was 57 mAU/ml. Conventional transcatheter arterial chemoembolization was initially performed for the local recurrence at the S5 operation site. In August 2013, sorafenib monotherapy was initiated with a dose of 400 mg orally once daily due to the patient s low body mass index of 17.3 kg/m 2 . Three weeks later, a dose reduction 200 mg once daily was necessary due to grade 3 hand-foot syndrome HFS , based on the Common Terminology Criteria for Adverse Events version 4.0 . Seven weeks later, he presented with acute cholangitis, that was treated and controlled by antibiotics Fig. 2 , during which sorafenib was temporarily discontinued. Approximately one month later 3 months after initialization of treatment , sorafenib was resumed at a dose of 200 mg every other day. During this time, tumor markers decreased to normal levels AFP, 3.8 ng/ml ; PIVKA 33 mAU/ml . After one month, his condition was continuously stable, therefore, the dose was increased to 200 mg per day. In April 2014 after 8 months , upon magnetic resonance imaging, the previously identified masses had disappeared, judged to be CR by the Response Evaluation Criteria in Solid Tumors Fig. 3 . Since then, the patient continued treatment. However, in May 2016, the treatment was interrupted as a result of a surgical procedure for heart valve disease. As of February 2018, he is in a continuous CR state with no medications being taken Fig. 4 .
Discussion
Sorafenib is the only multikinase inhibitor that blocks receptor tyrosine kinases, such as vascular endothelial growth factor receptor and platelet-derived growth factor receptor, as well as RAF serine / threonine kinases along the RAF / MEK / ERK pathway 6 . Thus, sorafenib targets both tumor cell proliferation and angiogenesis.
The efficacy of sorafenib has been demonstrated in two multicenter, phase , double-blind, placebo-controlled trials. The SHARP trial looked at over 600 patients with advanced HCC and Child-Pugh A cirrhosis, previously untreated with systemic therapy. The trial randomized patients to sorafenib 400 mg twice daily or placebo. Among patients treated with sorafenib, only seven 2 were considered responders according to the Response Evaluation Criteria in Solid Tumors. The study was stopped early when results revealed a longer overall median survival for patients treated with sorafenib versus placebo 10.7 vs. 7.9 months ; hazard ratio, 0.69 ; P 0.001 with a 31 relative reduction in risk of death 4 . Similar results were found in a second phase clinical study carried out in the Asia-Pacific region 3.3 partial response ; overall survival with sorafenib vs. placebo, 6.2 vs. 4.1 months ; hazard ratio, 0.67, P 0.016 5 . However, no CRs were reported in the second study.
A nationwide survey conducted in Japan reported 18 cases of CR after sorafenib in patients with advanced HCC, among 3,047 patients CR rate, 0.6 7 . Other studies conducted in Korea, Spain, and Italy showed CR rates of 1.3 7 of 523 , 1.1 12 of 1,119 , and 1.1 3 of 278 , respectively [8] [9] [10] . It should be noted however, that there were no reports of bone metastases in CR cases from any study. A literature search of case reports revealed only 2 HCC patients with bone metastases who achieved CR with sorafenib therapy in combination with a different agent 11 12 . The first case was a 64-year-old man with hepatitis B virus infection, who developed bone metastases 9 months after resection of HCC. Sorafenib therapy plus zoledronic acid was initiated. The patient achieved CR after 15 months of therapy and there was no sign of recurrence 12 months following treatment cessation. Regarding toxicity, the patient developed a grade 2 HFS reaction that required a temporary 50 dose reduction of sorafenib 11 . The second case was a 60-year-old man who developed extrahepatic metastases in bone, peritoneum, and lymph nodes after hepatectomy for HCC. As a pretreatment for sorafenib, the patient was treated using a combination therapy of oral fluoropyrimidine anticancer agent S-1, IFN, and zoledronic acid ; however, it was a progressive disease. Therefore, the patient was treated with sorafenib 800 mg/day but developed a grade 3 HFS reaction. He continued to be treated with sorafenib at a very low dose 200-400 mg/week plus denosumab. The response to combination therapy was graded as CR achieved at 6 months. Sorafenib was continued for 8 months and the patient remained in CR for 11 months 12 .
Bone metastasis leads to skeletal-related events, including pathologic fractures, a need for radiation or surgical treatment, and spinal cord compression, all of which impair the patient s quality of life. Clinical studies have shown that bone-modifying agents such as zoledronic acid and denosumab can reduce the incidence of skeletal-related events [13] [14] [15] . The first case involved combination therapy with zoledronic acid. Katamura et al 13 reported that zoledronic acid delayed the progression of bone metastases from HCC. The second case involved combination therapy using denosumab. Surprisingly, in this case, the dose of sorafenib was very low. Nakano et al 12 proposed that either sorafenib or denosumab produced an effective response for bone metastases, and a late response to IFN was possible. In any event, these two cases did not use monotherapy, but used combination therapy instead. Sorafenib monotherapy was used in our case due to the patient s request of not using a bone-modifying agent for his treatment. To our knowledge, this represents the first evidence of CR to sorafenib monotherapy for HCC with bone metastases. It is well known that bone-modifying agents are effective, and we believe that bone-modifying agents should be used in combination with sorafenib for similar cases of bone metastases in the future.
In our case, we started sorafenib monotherapy at a half-dose of 400 mg/day due to the patient s age of 67 years and a slender body type body mass index of 17.3 kg/m 2 . Despite a decrease in the initial dosage, our patient still experienced adverse events ; therefore, the dose was further reduced. At 3 months after initialization of treatment, by continuing low-dose treatment, the patient s AFP normalized, and CR was achieved by 8 months. He maintained a CR state for more than 2 years without any new adverse events. After 31 months, treatment was discontinued as a result of a surgical procedure for heart valve disease. To date, 22 months after discontinuation, he still maintains a CR state.
In summary, we report the first case of CR in a patient with advanced HCC with multiple lymph node and bone metastases treated with sorafenib monotherapy for 8 months.
